Eledon's Tegoprubart Achieves 100% Insulin Independence in T1D Trial

Eledon Pharmaceuticals announced updated positive results from an investigator-initiated trial evaluating tegoprubart in type 1 diabetes patients undergoing allogeneic islet cell transplantation. All 12 patients (100%) achieved insulin independence, no longer requiring exogenous insulin therapy, and demonstrated an HbA1c below 6.5%, with a mean of approximately 5.4%. This represents an average 2.6% improvement from baseline, with no severe hypoglycemic episodes reported post-transplant. The tegoprubart-based immunosuppression regimen was well tolerated, avoiding toxicities associated with calcineurin inhibitors, and the company plans to seek regulatory guidance from the FDA later this year.